The AtheroGene study and Leicester Acute Myocardial Infarction Peptide (LAMP) study by khan et al. have demonstrated that MR-proADM adds prognostic information beyond traditional risk models and biomarkers like BNP and NT-proBNP. This evidence concerns the gene NPPB and acute myocardial infarction.